Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to -$7.4 million.

  • Spero Therapeutics' Consolidated Net Income rose 5828.48% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.4 million, marking a year-over-year decrease of 72916.42%. This contributed to the annual value of -$68.6 million for FY2024, which is 35661.29% down from last year.
  • Latest data reveals that Spero Therapeutics reported Consolidated Net Income of -$7.4 million as of Q3 2025, which was up 5828.48% from -$1.7 million recorded in Q2 2025.
  • Spero Therapeutics' Consolidated Net Income's 5-year high stood at $55.1 million during Q4 2023, with a 5-year trough of -$30.1 million in Q1 2022.
  • Moreover, its 5-year median value for Consolidated Net Income was -$13.9 million (2025), whereas its average is -$10.1 million.
  • Per our database at Business Quant, Spero Therapeutics' Consolidated Net Income surged by 20021.88% in 2022 and then crashed by 45402.19% in 2024.
  • Spero Therapeutics' Consolidated Net Income (Quarter) stood at -$27.4 million in 2021, then soared by 200.22% to $27.5 million in 2022, then skyrocketed by 100.51% to $55.1 million in 2023, then tumbled by 137.03% to -$20.4 million in 2024, then skyrocketed by 63.82% to -$7.4 million in 2025.
  • Its Consolidated Net Income was -$7.4 million in Q3 2025, compared to -$1.7 million in Q2 2025 and -$13.9 million in Q1 2025.